AlzeCure’s Alzheimer project initiates Phase I study
pharmafile | October 4, 2021 | News story | Sales and Marketing |
Swedish pharmaceutical company AlzeCure Pharma AB has announced the initiation of the company’s next clinical Phase I trial (multiple ascending dose [MAD]), using the candidate drug ACD956, focused on Alzheimer’s disease. The first participant has already been dosed.
The primary aim of the study is to evaluate ACD856’s tolerability, safety, and efficacy after repeated dosing.
AlzeCure develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease, pain, and other conditions characterised by cognitive dysfunction.
Martin Jönsson, CEO of AlzeCure Pharma AB, comments: “It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up Phase I study where we will evaluate repeated dosing of ACD856.
“In August, we reported data from our SAD Phase I study, where we evaluate single administrations of ACD856 at different doses, which showed that the candidate drug has good tolerability and is suitable for further clinical development such as oral treatment of, among other things, Alzheimer’s disease. I am very much looking forward to the continued development of ACD856 and in the next step to initiate early efficacy studies.”
The MAD Phase I trial is AlzeCure’s third clinical study with ACD856, which is the lead candidate drug within the company’s NeuroRestore platform. It is being developed as a symptom-relieving treatment for disease states where the cognitive ability is impaired, such as in Alzheimer’s disease.
The compounds in the NeuroRestore platform stimulate several important signaling pathways in the brain to improved cognition. Preclinical studies have shown evidence for AlzeCure’s candidate drug strengthening the communication between nerve cells and improving cognitive ability, including memory functions.
Lina Adams
